Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Magnetic imaging agent
Patent
1992-02-20
1993-10-05
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Magnetic imaging agent
128654, 1286534, 436173, 514502, 556 45, 556 50, 556138, A61K 4900, A61B 600
Patent
active
052502856
ABSTRACT:
An NMR contrast agent composition contains a complex of a selected metal ion and a selected ligand. The ion is selected from the group consisting of gadolinium (III), iron (III), manganese (II), manganese (III), chromium (III), copper (II), dysprosium (III), terbium (III), holmium (III), erbium (III), europium (II), and europium (III); and the ligand is a linear two-nitrogen compound having one 2 hydroxy-aryl group at one of the nitrogens; or the ligand is a linear two-nitrogen compound having one or two 2-hydroxy aryl groups at each of the nitrogens; or the ligand is a linear three-, four-, or five nitrogen compound having one or two 2-hydroxy-aryl substituents at each of one or more of the nitrogens, or the ligand is a heterocyclic compound having a ring containing three or four nitrogens, and having a 2 hydroxy aryl substituents at one or more of the nitrogens; or the ligand is a heterocyclic compound having a ring containing 4 nitrogens, and having a carboxyl group at two of the nitrogens and an aromatic substituent at the other two of the nitrogens. Also, a method for enhancing the contrast in NMR imaging in a patient includes steps of preparing an NMR contrast enhancing agent by mixing an NMR contrast compound of the invention with a pharmaceutically acceptable carrier, introducing the NMR contrast enhancing agent into the patient, and subjecting the patient to NMR imaging.
REFERENCES:
patent: 3632637 (1972-01-01), Martell
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4687658 (1987-08-01), Quay
patent: 4714607 (1987-12-01), Klaveness
patent: 4746507 (1988-05-01), Quay
patent: 4834964 (1989-05-01), Rosen
patent: 4859451 (1989-08-01), Quay et al.
patent: 4880008 (1989-11-01), Lauffer
patent: 4885363 (1989-12-01), Tweedle et al.
patent: 4899755 (1990-02-01), Lauffer et al.
patent: 4963344 (1990-10-01), Gries et al.
Lauffer, Chem. Rev. 87: 901, 1987.
Brittain et al., Inorg. Chem. 23: 4459, 1984.
Martell, "The Design and Synthesis of Chelating Agents", p. 67 in Martell et al., eds., Development of Iron Chelators for Clinical Use, Elsevier North Holland, Inc., 1981.
Davison, "Protein Binding" in La Du et al., eds., Fundamentals of Drug Metabolism and Drug Disposition, R. E. Krieger Pub. Co., Malabar, Fla. 1971 Rocklage et al., Inorg. Chem. 28: 477, 1989.
Taliaferro et al., Inorganica Chimica Acta, 85: 9, 1984.
Taliaferro et al., Inorg. Chem 23: 1188, 1984.
Rocklage et al., Inorg. Chem 27: 3530, 1988.
Lauffer et al., J.A.C.S. 109: 2216, 1987.
Moore et al., Inorg. Chem. 28: 1504, 1989.
Konishiroku Photo Industry Co., Ltd., 74-Radiation Chem; Photochem, vol. 101, p. 537, abstract 219677p, 1984.
Taliaferro et al., New Multidentate Ligands. XXIV. Disodium-N,N'bis(2-hydroxy-5-sulfobenzyl)ethylenediamine diacetic acid, . . . trivalent metal ions, Chemical Abstracts 101:369 No. 44224j, 1984.
Phenolic derivatices of (hydroxyalkyl)alky=lenediamineacetic acids and their salts, Chemical Abstracts 89:561, 1978.
Martell et al., Inorganica Chimica Acta, vol. 138, 1987, pp. 215-230.
Larsen Scott K.
Lauffer Randall B.
Criares T. J.
The General Hospital Corporation
Waddell Frederick E.
LandOfFree
Hydroxy-aryl metal chelates for diagnostic NMR imaging does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydroxy-aryl metal chelates for diagnostic NMR imaging, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxy-aryl metal chelates for diagnostic NMR imaging will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1002146